Compare GRDN & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRDN | NEO |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Precision Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2023 | 2008 |
| Metric | GRDN | NEO |
|---|---|---|
| Price | $37.41 | $18.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $40.60 | $13.38 |
| AVG Volume (30 Days) | 337.7K | ★ 2.0M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,448,685,000.00 | N/A |
| Revenue This Year | N/A | $10.63 |
| Revenue Next Year | $7.63 | $9.73 |
| P/E Ratio | $117.77 | ★ N/A |
| Revenue Growth | ★ 17.93 | N/A |
| 52 Week Low | $23.18 | $7.07 |
| 52 Week High | $47.02 | $19.76 |
| Indicator | GRDN | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 66.75 |
| Support Level | $35.56 | $11.49 |
| Resistance Level | $38.12 | N/A |
| Average True Range (ATR) | 1.33 | 0.69 |
| MACD | -0.14 | 0.11 |
| Stochastic Oscillator | 8.21 | 61.39 |
Guardian Pharmacy Services Inc is a pharmacy services company providing technology-enabled services to help residents of long-term health care facilities (LTCFs) adhere to appropriate drug regimens, reducing the cost of care and improving clinical outcomes. The Company provides high-touch clinical, drug dispensing, and administration services tailored to residents in assisted living facilities, behavioral health facilities, and group homes, while also serving residents in all types of LTCFs. It partners with residents, LTCFs, and health plan payors to help reduce errors in drug administration, manage drug regimens, and improve adherence. The Company derives its revenue mainly from the sale of pharmaceutical and medical products.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.